©The Author(s) 2026.
World J Gastroenterol. Feb 28, 2026; 32(8): 113861
Published online Feb 28, 2026. doi: 10.3748/wjg.v32.i8.113861
Published online Feb 28, 2026. doi: 10.3748/wjg.v32.i8.113861
Table 1 Molecular pathology
| Tumor type | Mutated gene |
| Pancreatoblastoma: (NCI COMPASS) | Pathogenic: CTNNB1, GRIN2A |
| VUS: ACIN1, CDKL2, CHRNA2, DCHS2, ERBIN, FCRL3, FNDC1, GLDC, GMPS, GRID2, IL23A, JAK3, KRT34, L3MBTL3, LTBP2, MAML1, MRPS30, NRP2, OR51M1, PCDH19, PPM1N, PRDM10, SETD6, SGPL1, SLC27A6, SMAD4, SORBS3, SP100, SPATC1 L, TBXA2R, TCHP | |
| PACC: (NCI COMPASS) | Pathogenic: KRAS Q61H, CREBBP, PRKAR1A, TGFBR2 |
| CNV: Amplification, AKT3, NTRK1, MDM4; loss: RB1, BRCA2 | |
| VUS: ATR, CHD4, FGF6, FGFR3, LAMP1, LRP1B, MGA, PRKDC, SETD2, SLX4, ZBTB7A, ZFHX3 |
- Citation: Skorupan N, Sperling D, Nutting C, Miettinen M, Cohn A, Alewine C. Use of yttrium-90 radioembolization to control liver metastases in pancreatic acinar cell carcinoma and pancreatoblastoma: Two case reports. World J Gastroenterol 2026; 32(8): 113861
- URL: https://www.wjgnet.com/1007-9327/full/v32/i8/113861.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i8.113861